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KAJIAN PENGKOMPUTERAN KE ATAS FLAVONOID SEMULAJADI 
KE ARAH PENEMUAN PERENCAT XANTINA OKSIDASE 
 
ABSTRAK 
 
Xantina oksidase (XO) memangkinkan penukaran hipoxantina kepada 
xantina dan seterusnya xantina kepada asid urik. Peningkatan paras asid urik di 
dalam serum darah dikenali sebagai hiperurisemia boleh menyebabkan 
komplikasi seperti sakit sendi dan batu karang. Allopurinol telah diperkenalkan 
pada tahun 1966, merupakan ubat yang paling berkesan untuk merencatkan 
aktiviti XO, seterusnya mengurangkan kepekatan asid urik dalam darah. Namun 
demikian, allopurinol memberi beberapa kesan sampingan yang serius 
terhadap pesakit, dan kadang-kala boleh membawa maut. Oleh itu, usaha 
pencarian inhibitor baru yang memberikan kesan sampingan yang rendah tetapi 
beraktiviti tinggi amatlah diperlukan dengan segera. Inhibitor yang berpontensi 
mungkin boleh diperolehi daripada sumber semulajadi, seperti flavonoid, di 
mana ia banyak digunakan dan telah menunjukkan aktiviti perencatan terhadap 
XO.  
 
Kajian ini bertujuan untuk menyelidik potensi flavonoid sebagai inhibitor 
XO. Peringkat pertama dalam kajian ini melibatkan penapisan perpustakaan 
flavonoid yang mengandungi sejumlah 125 sebatian, dengan menggunakan 
perisian pendokkan molekular DOCK 6.0. Seterusnya AutoDock 3.0.5 
digunakan untuk mengkaji 35 flavonoid yang menduduki kedudukan teratas 
dalam DOCK 6.0. Likoisoflavone-A yang diekstrak daripada akar Glycyrrhiza 
glabra Leguminosae (liquorice) mempunyai aktiviti yang paling tinggi terhadap 
perencatan XO. 
 xviii
 Untuk lebih memahami interaksi di antara flavonoid dan XO, simulasi 
dinamik molekular telah dijalankan. Sistem pertama melibatkan inhibitor 
berpotensi yang berada di kedudukan teratas daripada pengiraan pendokkan  
contohnya likoisoflavone-A dan sistem kedua ialah quercetin dimana ia telah 
dikenalpasti mempunyai aktiviti “perencatan bersaing” terhadap XO. Daripada 
trajektori simulasi dinamik, MMPBSA telah digunakan untuk mengira afiniti 
pengikatan untuk dua ligan tersebut terhadap XO. Keputusan yang diperolehi 
menunjukkan korelasi yang baik dengan keputusan daripada AutoDock 3.0.5 
dan DOCK 6.0. Ini menunjukkan likoisoflavone-A mungkin mempunyai potensi 
yang tinggi untuk merencat XO. Kajian juga menunjukkan interaksi hidrofobik 
memainkan peranan penting untuk menghasilkan pengikatan yang lebih baik di 
antara flavonoid dan XO. Peningkatan bilangan karbon alifatik ke atas struktur 
flavonoid dapat meningkatkan tahap kehidrofobikan molekul ini. 
Walaubagaimanapun, kriteria ini tidak semestinya dapat meningkatkan aktiviti 
perencatan kerana rantainya yang panjang mungkin menghalang ligan untuk 
dimuatkan ke dalam tapak aktif seperti dalam kes erysubin-F dan papiriflavonol-
A. 
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 COMPUTATIONAL STUDIES OF NATURAL FLAVONOIDS TOWARDS THE 
DISCOVERY OF A POTENTIAL XANTHINE OXIDASE INHIBITOR 
 
 
ABSTRACT 
 
 
Xanthine oxidase (XO) catalyses the conversion of hypoxanthine to 
xanthine and subsequently xanthine to uric acid. The increase of uric acid level 
in blood serum, which called hyperuricemia, can lead to major complications 
such as gout and kidney stones. Allopurinol that was introduced in 1966 is the 
most effective drug to inhibit xanthine oxidase activity, thus lowering uric acid 
concentration. However, allopurinol exhibits severe side effects that sometimes 
can also lead to death. Therefore, there is an urgent need to discover a new 
inhibitor which has low side effects but high activity. Potential inhibitor may 
comes from natural sources, such as flavonoids which have been consumed in 
abundance that appear to show an inhibitory activity toward XO. 
 
The current study aims to investigate the potency of flavonoids as XO 
inhibitors. The primary stage of the study involved filtering of a library of 
flavonoids containing 125 compounds using molecular docking software, DOCK 
6.0. Subsequently, AutoDock 3.0.5 was used to further investigate the top 35 
ranked flavonoids obtained from DOCK 6.0. Licoisoflavone-A, which is 
extracted from the root of Glycyrrhiza glabra Leguminosae (Liquorice) shows 
the most potent activity toward the inhibition of XO. 
 
 
 
 xx
In order to understand the interaction between flavonoid and XO, 
molecular dynamics simulations were performed. The first system involved 
potential inhibitor that rank first in the docking calculations i.e. licoisoflavone-A, 
and the second system included quercetin as it is known to have competitive 
inhibitory activity on XO. From MD trajectories, MMPBSA was performed to 
calculate the binding affinities for the two ligands toward XO. The results 
correlated well with the findings from AutoDock 3.0.5 and DOCK 6.0. This 
indicates that licoisoflavone-A, might have high potential activity to inhibit XO. It 
has also been observed that the hydrophobic interactions make important 
contributions to improve binding between flavonoids and XO. Increasing the 
aliphatic carbons on the flavonoid structure has increased the hydrophobicity of 
the compound. Nevertheless, this criteria might not necessarily increase the 
inhibitory activity, as the long chain might prevent the ligand to fit into the active 
site, as with the case of erysubin-F and papyriflavonol-A. 
 
 
 
 xxi
 1
CHAPTER ONE 
INTRODUCTION 
 
 
1.1 Statement of the problem 
 
Xanthine oxidase (EC 1.17.3.2, XO) plays a key physiological role in the 
metabolism of purines which catalyse the hydroxylation reaction of hypoxanthine to 
xanthine, and subsequently xanthine to uric acid (Borges et al., 2002; Hille, 1996). 
Increase in the production of uric acid or decrease in the excretion will lead to 
increase in the uric acid levels in the body. The increase of uric acid levels in blood 
is called hyperuricemia (Sitori, 2000). Hyperuricemia leads to many complications 
such as gout and kidney stones. It may also be associated with renal insufficiency 
and cardiovascular diseases (Nakagawa et al., 2006). Hyperuricemia is identified 
when uric acid concentration is ≥ 7 mg/dl for men and ≥ 6 mg/dl for women 
(Schlesinger and Schumacher, 2002). 
 
Allopurinol (4-hydroxypyrazolo [3,4-d] pyrimidine), an analogue of 
hypoxanthine, is a specific potent inhibitor and substrate for XO (Fields et al., 
1996). It has been used to treat individuals suffering from hyperuricemia of gout. 
This drug is slowly oxidized to oxypurinol, a xanthine analogue, which is a more 
potent XO inhibitor. The most common adverse effects of allopurinol include 
hypersensitivity reactions, skin rashes and gastrointestinal distress. However, 
these effects always occur in individuals with reduced glomerular filtration. 
Syndromes of allopurinol toxicity including rashes, fever, worsening of renal 
insufficiency, vasculities, easinophilia and death have been reported (Bouloc et al., 
 2
1996; Horiuchi et al., 2000). These syndromes appear to be more common in the 
elderly patients with renal insufficiency. Moreover, safety in children and during 
pregnancy has not been established (Borges et al., 2002). Thus, there is an urgent 
need to discover compounds with XO inhibitory activities but devoid of the 
undesirable effects of allopurinol. One potential source of such compounds is 
medicinal materials of plant origin which are used to treat conditions similar to 
gouty arthritis. 
 
Flavonoids belong to a group of natural substances with variable phenolic 
structures and are found in fruit, vegetables, grains, bark, roots, stems and flowers. 
Researches on flavonoids have suggested these compounds might act as active 
inhibitors for XO (Cos et al., 1998).  Thus, the aim of this study is to investigate the 
potency of natural flavonoids, as XO inhibitors, using molecular modelling 
techniques.  
 
Molecular modelling approach has become a major part of rational drug 
design. Traditional drug design cycle to introduce active compounds is considered 
too slow and costly. Recently, new methods of processing very large libraries of 
potentially bioactive small molecules through molecular modelling methods have 
constantly played an important role in drug discovery. It is hoped that new 
inhibitors of XO will be discovered by using molecular modelling techniques such 
as molecular docking and molecular dynamics simulations.  
 
 3
1.2 Hyperuricemia 
 
Hyperuricemia is defined when serum uric acid levels exceed 7 mg/dl for 
men and 6 mg/dl for women. Uric acid is the final product of purine metabolism and 
these catabolic steps are catalysed mainly by XO enzyme as shown in Figure 1.1. 
During catabolism, hypoxanthine will be oxidized to xanthine and furher to uric 
acid, which cannot be further metabolised and will be eliminated through the gut 
and the kidneys (Mandell, 2002; Luk and Simkin, 2005). 
 
Hyperuricemia can be caused by overproduction of uric acid or insufficient 
excretion by kidneys. Some of the causes that increase the uric acid productions 
are: 
i- High purine diet (e.g. meat, seafood, alcohol) 
ii- Cytotoxic therapy (i.e. drugs and radiotherapy) 
iii- Myocardial infarction 
iv- Specific enzyme defects 
 
Insufficient uric acid excretion from kidneys can arise from different reasons 
such as, alcohol intake, drugs (e.g. diuretics) and renal failure. In addition, 
estrogen is another factor which is believed to promote uric acid excretion in the 
urine, which explains why men have high risk of developing hyperuricemia 
compared to women. However, involvement of more than one factor has been 
reported such as a combination of overproduction and low excretion of uric acid, 
high alcohol consumption and Glucose-6-phosphatase deficiency, indicating that 
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hyperuricemia is a multifactorial disorder leading to a complicated diseases like 
gout urolithiasis (Dincer et al., 2002). As these factors are suspected in high 
percentage in adults, 10% of adults are documented to have hyperuricemia at least 
once in their life. Therefore, it is worth to look for an agent/s which participates in 
alleviating or preventing this common disorder (Hayden and Tyagi, 2004). In the 
following paragraphs an overview on complications caused by hyperuricemia in 
order to understand the principal factors behind these disorders and then looking 
for the possible treatment targets will be presented. 
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Figure 1.1: Schematic diagram for purine catabolism pathway. XO is xanthine 
oxidase, GMP is guanosine monophosphate, AMP is adenosine 
monophosphate, ADP is adenosine diphosphate, ATP is adenosine 
triphosphate and IMP is inosine 5'-monophosphate 
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1.2.1 Complications of Hyperuricemia 
 
The major complications of hyperuricemia are gout, urolithiasis, reactive 
oxygens production and acute uric acid nephropathy. In addition to that, some 
diseases are frequently seen with elevated uric acid concentration such as 
cardiovascular disease, although no direct role has yet been confirmed (Pascual 
and Pedraz, 2004). 
 
1- Gout 
 
Gout is a metabolic disorder characterised by high levels of uric acid 
in the blood (hyperuricemia). This hyperuricemia results in the deposition of 
crystals of sodium urate in tissues, especially in kidneys and joints. 
Hyperuricemia does not always lead to gout but gout is always preceded by 
hyperuricemia. The deposition of urate crystals initiates an inflammatory 
process involving the infiltration of granulocytes that phagocytize the urate 
crystals (Figure 1.2). This process generates oxygen metabolites, which 
damage tissue, resulting in the release of lysosomal enzymes that induce an 
inflammatory response. In addition, lactate production in the synovial tissue 
also increases. This will lead to local decrease of pH which further cause 
more deposition of urate crystals (Mycek et al., 2000). 
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Figure 1.2: Role of uric acid in the inflammation of gout 
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The diagnosis of gout is based on the presence of monosodium urate 
crystals in the synovial fluid or tophi (Weselman and Agudelo, 2001). This 
deposition will exacerbate leading to recurrent episodes of acute arthritis, the 
classic manifestation of gout. It should be noted that different factors are 
participating in the development and progress of this diseases as well. The 
incidence of gout rises dramatically with age. It has been hypothesized that 
estrogen will act as a protecting agent against urate deposition, by promoting renal 
excretion of uric acid. Therefore the overall men:women ratio ranged between 7:1 
and 9:1. Factors like inherited enzyme deficiencies, obesity, decrease renal 
function, hypertension and alcohol also play a role (Wright and Pinto, 2003). It has 
been identified that 20% of gouty patients make renal stones (Foye, 1995). 
 
Understanding all the above mentioned factors and the complicated 
mechanism will help us in identifying what type of gout we are targeting for the 
treatment as the treatment of gout depends on the type of attack.  Acute gouty 
attacks therapies mainly include nonsteroidal ant-inflammatory drugs (NSAIDs) or 
colchicine. Meanwhile, controlling the uric acid level in the blood is still the main 
target particularly in the management of the chronic attacks. Examples of such 
drugs are allpurinol, probenecid and sulfinpyrazone (Mandell, 2002; Weselman and 
Agudelo, 2001). 
 
 
 
 
 9
2- Urolithiasis 
 
Urolithiasis is the process of stone formation in kidneys and other urinary 
ailments. Stone formation is not itself a specific diseases, it is much more 
complicated than that. Urolithiasis is a multifactorial disease and presents a final 
stage of a complication of many different diseases (Foye, 1995). For stone to be 
formed, many factors have to be involved however supersaturation of urine with 
regards to the crystal components from time to time is prerequisite for the 
crystallization process to be initiated leading to crystal formation and precipitation. 
Crystals are of different types and one of them is uric acid crystals. There are two 
types of deposits, one that composed of uric acid and other composed of urate. pH 
of the urine has been found to influence the availability and solubility of 
substances. Studies showed that pH will determine the type of deposition, in which 
acidic media (pH 3.7) is suitable for uric acid deposition while at higher pH (pH 7.4) 
is suitable for urate deposition (De Vries and Sperling, 1977). 
 
Uric acid stones account for 5-10% of all renal stones in the United States. 
Not all stones in hyperuricemic patients are composed primarily of uric acid, but 
uric acid acts as a nidus for the formation of different stones mainly calcium stones 
(Dincer et al., 2002). 
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3- Reactive Oxygen Species (ROS) Free Radical Production induced by XO 
 
Reactive oxygen species (ROS) include oxygen ions, free radicals and 
peroxides. ROS are generally very small molecules and are highly reactive due to 
the presence of unpaired valence shell electrons. During uric acid production 
pathway, hypoxanthine will be hydroxylised to xanthine and then to uric acid via an 
enzyme called xanthine oxidase (XO). Enzyme xanthine oxidase produces ROS 
during the oxidative half reaction, which takes place in the binding of FAD of the 
reduced form of XO with oxygen molecule. This reaction will lead to transfer of 
electrons from the reduced form of XO to the oxygen according to following 
reaction in the Scheme 1.1 (Mondal et al., 2000): 
 
(XO)reduced + O2   (XO)reduced•O2 (XO)oxidized + O2•-  
 
Scheme 1.1 
 
The presence of high quantity of these radicals have been strongly 
responsible for disturbing  cell physiology associated to oxidative stress such as 
cancer inflammation and arterioscleroses (Da Silva et al., 2004; Van Hoorn et al., 
2002) 
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1.2.2 Therapeutic strategies for preventing the complications 
 
 
Most of the therapeutic strategies for hyperuricemia focus on lowering uric 
acid level in the blood below the saturation point, thus preventing the deposition of 
urate crystals. This can be achieved by interfering with uric acid synthesis via 
inhibiting XO enzyme e.g. by using allopurinol or by increasing uric acid excretion 
e.g.  using probenecid or sulfinpyrazone (Mycek et al., 2000). 
 
Prevention of conversion of XO to the reduced form will lead to inhibition of 
ROS formation (Cotelle et al., 1996a). Thus, in this study, the strategy is to inhibit 
XO as a measure for the management of hyperuricemia. By inhibiting XO activity, 
uric acid and superoxides production will be ceased. 
 
1.3 Xanthine Oxidase (EC 1.17.3.2) 
 
Xanthine oxidase (XO) is a molybdoflavoenzyme which can be found in 
almost all species. The human enzyme is widely distributed with the highest levels 
are in liver and intestine (Parks and Granger, 1986). XO from human breast milk 
has been purified and characterised successfully in 1986 (Krenitsky et al., 1986). 
Bovine milk XO is widely available, thus it has been known for 100 years and 
studied in its pure form for over 60 years, therefore it has been used in most of the 
studies (Patton and Keenan, 1975). XO has high amino acids sequence homology 
among the mouse, rat, bovine and human enzymes with about 90% identity, and 
consisting of about 1,330 amino acids (Nishino, 1994; Borges et al., 2002; Godber 
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et al., 2005). Studies showed the existence of similar physicochemical properties of 
XO between human and bovine milk, but it has only approximately 5% of the 
activity of the bovine milk enzyme towards xanthine and related substrates  
proposing that the low activity is due to grossly deficient of molybdenum (Abdeh et 
al., 1992). XO is distributed in most of the tissues, with high levels in liver and 
intestine. Microscopic studies of cultured human endothelial cells showed that XO 
is present in cytoplasm and also on the outer surface of the cell membrane 
(Harrison, 2002).  
 
The X-ray crystal structure of bovine milk XO has been released in the 
Protein Data Bank (www.pdb.org) in August 2000 with a PDB code entry of (1FIQ) 
(Enroth et al., 2000). The structure has been used in this study due to X-ray 
structure availability and similar physicochemical properties with human XO. While 
the X-ray crystal structure for human XO has been released on May 2007 with a 
PDB code entry of (2CKJ) (Pearson et al., 2007).  
 
Bovine milk XO enzyme obtained from the protein data bank (PDB entry 
1FIQ). The crystal structure  is a homodimer of 145 kDa subunits, which consists of 
a 20-kDa N-terminal domain containing two iron-sulfur centers, a 40-kDa middle 
domain containing flavine adenine dinucleotide (FAD), and an 85-kDa C-terminal 
containing the molybdopterin cofactor (Kisker et al., 1998; Mondal et al., 2000; 
Borges et al., 2002). The monomer can be divided into three domains, the small N-
domain starts from residue 1 to 165, and contains both iron/sulfur cofactors that is 
connected to the second domain (FAD-binding domain) residues 226 to 531 by 
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segment of residues 166 to 225. FAD also connected to the third domain by 
another linker composed of residues 532 to 589.  The large third domain (residues 
590 to 1,332) is the molybdopterin cofactor (Figure1.3) (Enroth et al., 2000). 
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Figure 1.3: Crystal structure of bovine milk XO (1FIQ) from Protein Data Bank 
(entry code: 1FIQ) 
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1.3.1 Active site of XO 
 
 
The crystal structures of bovine milk XO suggests that hypoxanthine and 
xanthine bind to the C-terminal domain of the XO, close to the molybdopterin 
cofactor. During substrate oxidation, the Mo centre is first reduced by electron 
received from the substrate and subsequently re-oxidized, as the electron passes 
first to the iron- sulfur centres and then to the FAD centre, and are finally donated 
to NAD+ or O2 (Hille and Nishino, 1995; Kisker et al., 1998; MacMaster and 
Enemark:, 1998). The mechanism of uric acid production will be discussed in 
Section 1.3.3. Salicylate was crystallised with XO as a competitive inhibitor, which 
binds to the binding site of the enzyme inhibiting xanthine or hypoxanthine to bind 
and be metabolised by XO. The amino acid that plays an important role in the 
catalytic reaction specified by Hille et al. (2004) is Glu 1261 (Figure 1.4) (Hille et 
al., 2004). The enzyme complex with salicylate shows that both the carboxylate 
atoms are close to the guanidinium group of Arg 880 (3.0 Å and 3.1 Å). An 
interaction with Glu 1261 can be involved via water 230. Hydrogen bond can be 
formed between the hydroxyl group of salicylic acid with both amide and hydroxyl 
side chain of Thr 1010. The aromatic ring of Phe 914 slightly overlaps with salicylic 
acid ring, on the other hand,  salicylate ring forms a T-shape aromatic interaction 
with Phe 1009 ring (Enroth et al., 2000).  
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Figure 1.4: Amino acid residues that contribute in the catalytic reaction in the 
active site 
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1.3.2 Mechanism of action of XO 
 
 
The reaction of XO composed of two catalytic reactions, reductive half and 
the oxidative half reaction. The reductive half reaction is the conversion of xanthine 
to uric acid, which takes place in the molybdenum centre of the enzyme. In this 
reaction, Mo(VI) is converted to its reduced form Mo(IV). While the oxidative half 
reaction takes place at the FAD centre, and  oxidize Mo(IV) to Mo(VI) by molecular 
oxygen with the formation of ( •2O
-
 ) or H2O2  (Olson et al., 1974; Huber et al., 
1996). 
 
The oxidative part of the reaction involves the binding of molecular oxygen 
to the FAD centre of the reduced form of XO. This will lead to the transfer of 
electrons from the reduced form, to achieve enzyme oxidation (Hille and Massey, 
1981) as shown in Scheme 1.2. Slow and fast phase in this reaction have been 
observed, and six electrons are transferred throughout the reaction (Hille and 
Massey, 1981; Mondal et al., 2000) as shown in Scheme 1.3. The fast phase 
involves in the transfer of five electrons and the formation of hydrogen peroxide 
(H2O2) and superoxide ( •2O
-
 ). Whereas the slow phase includes the oxidation of 
one electron and the formation of superoxide only (Mondal and Mitra, 1996) as 
given in Scheme 1.4. The mechanism of the formation of xanthine and uric acid is 
considered as the reductive half reaction (Scheme 1.5) (Kim et al., 1996). Further 
discussion will be presented in the next section. 
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Scheme 1.2 
 
 
Scheme 1.3 
 
 
Scheme 1.4 
 
 
Scheme 1.5 
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1.3.3 Mechanism of uric acid production 
 
Many researchers studied the catalytic reaction of XO proposing different 
mechanisms on the source and the way to incorporate the oxygen atom that is 
used to oxidize the substrate. But they all share the same concept, which is the 
hydroxylation to C-8 of xanthine. 
 
In the early days of identifying the mechanism, it was proposed that the 
oxygen source is derived from water (Murray et al., 1966). However, it has been 
shown later that the oxygen atom incorporated into product is derived from the 
catalytically labile site of the enzyme, which must then be regenerated with oxygen 
from water. In addition, it has been suggested that the catalytically labile site of XO 
is in fact the Mo=O of the enzyme. A mechanism of action has been proposed in 
which the catalysis proceeds via deprotonation of C-8 position of xanthine, or 
hypoxanthine, followed by nucleophilic attack of the resultant carbanion on the 
Mo(VI)=O group to give Mo(IV)-O-R species (Hille and Sprecher, 1987), as shown 
in  Scheme 1.6. The abstraction of C-8 hydrogen by Mo=S group is compatible 
with the known acidity of this position of xanthine (pKa ~14) and the Mo=S is 
sufficiently basic to protonate upon reduction of the enzyme. Furthermore, it 
appears that the reaction initiated by hydrogen abstraction followed by carbanion 
attack on Mo=O is the more likely reaction rather than a hydride attack on Mo=S, 
which was proposed by Bray and co-workers (Bray et al., 1979). 
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A mechanism involving the metal-coordinate hydroxyl has been proposed 
for XO mechanism of action (Huber et al., 1996). The reaction is initiated by 
nucleophilic attack on C-8 of xanthine by the hydroxyl group to give a transient 
tetrahedral intermediate. This breaks down by hydride transfer to Mo=S group, with 
resultant reduction of the molybdenum to Mo(IV) valence state. It should be noted 
that the pKa for the C-8 position is also to be relatively low, to be suitable for 
nucleophilic attack, as specified in Scheme 1.7. 
Mo O
S
OH
S
S
N
N
H
N
H
NH
O
O
H
H
+
N
N
H
N
H
NH
O
O
Mo O
S
S
S O
H
H
N
N
H
N
H
NH
O
O
Mo O
SH
S
S ON
N
H
N
H
NH
O
O
Mo O
S
S
S
O
H
+
H
+
, e-
N
H
N
H
N
H
NH
O
O
O
Mo O
S
OH
S
S
H+
Uric acid
Xanthine
VI
IV
VI
VI
OH2
VI
 
Scheme 1.7 
 22
As shown in Scheme 1.8, this mechanism involves the reducing the Mo=S 
group to Mo-SH by abstracting the hydrogen from C8-H of xanthine, then the 
formation of molybdenum–C8 bond. This will incorporate hydroxide from solvent to 
yield the same intermediate as in the previous proposed mechanisms 
(Coucouvanis et al., 1991). 
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Pilato and Stiefel (1993) proposed that N-7/C-8 double bond adds across 
the Mo=O directly in a cyclo-addition, to give an intermediate that can be broken by 
hydride transfer to give a species different from that proposed previously. The 
Mo=O group must regenerated immediately in the catalytic sequence, and the 
water molecules can serve such purpose, as given in Scheme 1.9 (Pilato and 
Stiefel, 1993). 
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1.4 Flavonoids 
 
In nature, flavonoid compounds are products extracted from plants and they 
are found in several parts of the plants: leaves, fruits, etc. Flavonoids are used by 
the vegetables for their growth and defence against plagues (Havsteen, 2002). 
They are a class of low molecular weight phenolic compounds that are widely 
distributed in the plant kingdom. They constitute one of the most characteristic 
classes of compounds in higher plants. Many flavonoids are easily recognized as 
flower pigments in most angiosperm families. However, their occurrence is not 
restricted to flowers but includes all parts of plant (Dewick, 2001). The chemical 
structure of flavonoids is based on a C15 skeleton with two phenolic rings 
connected together by three carbon units as shown in Figure 1.5. Flavonoids are 
grouped according to the presence of different substituents on the rings and the 
degree of ring saturation. They are frequently attached with sugars moiety to 
increase their water solubility (Stumph and Conn, 1981). Flavonoids have several 
subgroups, which include chalcones, flavones, flavonols and isoflavones. Table 1.1 
shows the main subgroups of flavonoids. 
 
A novel Laureate, Albert Szent-Gyorgyi, Ph.D., who discovered vitamin C, 
had isolated the flavonoids (proanthocyanidins) in 1930’s. He found that flavonoids 
could strengthen capillary walls that vitamin C cannot. At the beginning, the 
flavonoids were recognized as vitamin P. Besides that, some chemist also 
classified flavonoids as a single vitamin. Nowadays, there are about 4,000 
flavonoids compounds that contribute to the colorful pigments of fruits, herbs and 
